Evidence map›Paper›PMID 29089599›Full record

ReviewThe Journal of antibiotics2017

Microbial metabolites and derivatives targeted at inflammation and bone diseases therapy: chemistry, biological activity and pharmacology.

Hayamitsu Adachi, Koichi Nakae, Shuichi Sakamoto, Chisato Nosaka, Sonoko Atsumi, Masabumi Shibuya, Nobuaki Higashi, Motowo Nakajima, Tatsuro Irimura, Yoshio Nishimura

Erratum issuedOpen access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in The Journal of antibiotics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Hayamitsu AdachiInstitute of Microbial Chemistry (BIKAKEN), Numazu Branch, Shizuoka, Japan.
Koichi NakaeInstitute of Microbial Chemistry (BIKAKEN), Tokyo, Japan.
Shuichi SakamotoInstitute of Microbial Chemistry (BIKAKEN), Numazu Branch, Shizuoka, Japan.
Chisato NosakaInstitute of Microbial Chemistry (BIKAKEN), Tokyo, Japan.
Sonoko AtsumiInstitute of Microbial Chemistry (BIKAKEN), Tokyo, Japan.
Masabumi ShibuyaJobu University, Gunma, Japan.
Nobuaki HigashiHoshi University, Tokyo, Japan.
Motowo NakajimaSBI Pharmaceuticals Co., Ltd., Tokyo, Japan.
Tatsuro IrimuraJuntendo University School of Medicine, Tokyo, Japan.
Yoshio NishimuraInstitute of Microbial Chemistry (BIKAKEN), Tokyo, Japan.
Microbial Chemistry Research Foundation · JPHoshi University · JPJobu University · JPJuntendo University · JPSBI Pharmaceuticals (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microbial metabolites have attracted increasing interest as a source of therapeutics and as probes for biological mechanisms. New microbial metabolites and derivatives targeted at inflammation and bone disease therapy have been identified by focusing on prostaglandin release, osteoblast differentiation and immune cell functions. These modulators of inflammatory processes and bone disease contribute to our understanding of biological mechanisms and support identification of the therapeutic potential of drug lead candidates. The present review describes recent advances in the chemistry and analysis of inhibitors of prostaglandin release or other functional molecules of immune cells, as well as inducers of osteoblast differentiation, including biological and pharmacological activities.The Journal of Antibiotics advance online publication, 1 November 2017; doi:10.1038/ja.2017.138.

Identifiers

PMID29089599
OpenAlexW2765860884

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.